ABUS Arbutus Biopharma Corporation

1.5
+0.08  (+6%)
Previous Close 1.42
Open 1.45
Price To Book 2.59
Market Cap 85,275,258
Shares 56,850,172
Volume 141,526
Short Ratio
Av. Daily Volume 518,983

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial ongoing but no plans to continue further development.
ARB-1467, tenofovir, and pegylated interferon
Hepatitis B (HBV)
Phase 2 Cohort 4 data released September 25, 2017 with detailed data due at AASLD in October 2017.
ARB-1467
Hepatitis B (HBV)
Phase 1 trial initiation delayed - noted October 9, 2018. Decision regarding clinical development due early 2020.
AB-452
Hepatitis B
Phase 1 final data due 1H 2020.
AB-506
Hepatitis B (HBV)
Phase 1a/b data due 1Q 2020.
AB-729
Hepatitis B (HBV)

Latest News

  1. Arbutus to Participate at Wedbush PacGrow Healthcare Conference
  2. Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates
  3. Arbutus Reports Second Quarter 2019 Financial Results and Provides Corporate Update
  4. Arbutus to Report Second Quarter 2019 Financial Results
  5. Will Arbutus Biopharma (ABUS) Report Negative Q2 Earnings? What You Should Know
  6. Arbutus Announces Preliminary Phase 1a/1b Clinical Trial Results for AB-506, an Oral Capsid Inhibitor in Development for People with Chronic Hepatitis B
  7. Here’s What Hedge Funds Think About Arbutus Biopharma Corp (ABUS)
  8. The Daily Biotech Pulse: Roche's Flu Drug Aces Late-Stage Trial, Acura Outlicenses Pain Medication, Neuronetics Gets New Finance Chief
  9. Arbutus Sells Part of its ONPATTRO™ (patisiran) Royalty Interest to OMERS
  10. Arbutus Gets Clearance to Initiate Hepatitis Study, Stock Up
  11. Arbutus receives regulatory clearance to initiate Phase 1a/1b Clinical Trial of AB-729
  12. Arbutus Appoints William Collier as Next President & CEO and Announces Retirement of Current President & CEO, Mark J. Murray Ph.D.
  13. Arbutus to Participate at JMP Securities Life Sciences Conference
  14. Is Arbutus Biopharma Corporation (NASDAQ:ABUS) Excessively Paying Its CEO?
  15. Arbutus to Present at Upcoming May 2019 Conferences
  16. Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates
  17. Arbutus: 1Q Earnings Snapshot
  18. Arbutus Reports First Quarter 2019 Financial Results and Provides Corporate Update
  19. Arbutus to Report First Quarter 2019 Financial Results
  20. Arbutus Biopharma (ABUS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release